Obstructive sleep apnea (OSA) affects up to 4% of the adult population. Hypoglossal nerve stimulation (HNS) was approved by the FDA in 2014 as a treatment option for patients with moderate to severe OSA who cannot tolerate CPAP and, since that time, studies have focused on predicting response to this therapy. This review summarizes the relevant literature assessing factors that predict HNS success including therapeutic response and device adherence.
© 2024 The American Laryngological, Rhinological and Otological Society, Inc.